Artimplant postpones Annual General Meeting and Interim Report

The Board has decided to put back the Annual General Meeting and the first
Interim Report for 2013 from May 7 to May 30, 2013. The decision is related to
the ongoing company evaluation work by the Board regarding the structure of the
company and ways to finance the company into a profitable and competitive
business of the future.

The Board intends to present the outcome of the work at the upcoming AGM on May
30, 2013.

Västra Frölunda, April 4, 2013

Kjell Thörnbring
CEO

For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 119 025

Further information is available at www.artimplant.com where you can also
subscribe to future press releases; www.artimplant.com/investors-media/subscribe
-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedics. We restore health through the development, production and marketing
of degradable implants that regenerate body functions and improve quality of
life. Our products, made from Artelon®, meet unmet clinical needs and are
marketed in a growing number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet as well as shoulder and other soft
tissue injuries.

Artimplant is a public company, listed on NASDAQ OMX Stockholm in the Small Cap
segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting on the Company's business, including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information that Artimplant will make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on April 4, 2013 at 3 pm (Swedish time).